Skip to main content

Table 1 Baseline clinical and pathological characteristics

From: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Characteristics

Enrolled patients

(n = 49)

Age (years)

Median

67 (61–75)

Gender

 

Male

29 (59%)

Female

20 (41%)

ECOG

0–1

38 (78%)

2

11 (22%)

Ann Arbor stage

II

9 (18%)

III

15 (31%)

IV

25 (51%)

LDH

Normal

8 (16%)

Elevated

41 (84%)

Extranodal sites

0–1

20 (41%)

 ≥ 2

29 (59%)

IPI

2

7 (14%)

3

17 (35%)

4

20 (41%)

5

5 (10%)

Cell of origin

GCB

14 (29%)

non-GCB

35 (71%)

Double expressor lymphoma

Yes

12 (25%)

No

37 (75%)

  1. ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, IPI International Prognostic Index
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us